Evidence map›Paper›PMID 33728101›Full record

ReviewImmune network2021

Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target.

Jaewoo Hong, Hyunjhung Jhun, Yeo-Ok Choi, Afeisha S Taitt, Suyoung Bae, Youngmin Lee, Chang-Seon Song, Su Cheong Yeom, Soohyun Kim

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immune network, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Jaewoo HongDepartment of Physiology, Daegu Catholic University School of Medicine, Daegu 42472, Korea.ORCID https://orcid.org/0000-0003-3456-3672
Hyunjhung JhunTechnical Assistance Center, Korea Food Research Institute, Wanju 55365, Korea.ORCID https://orcid.org/0000-0002-3694-9715
Yeo-Ok ChoiLaboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea.
Afeisha S TaittLaboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea.ORCID https://orcid.org/0000-0003-4504-1001
Suyoung BaeDepartment of Bioequivalence Division for Drug Evaluation, Ministry of Food and Drug Safety, Cheongju 28159, Korea.ORCID https://orcid.org/0000-0002-4092-6508
Youngmin LeeDepartment of Medicine, Pusan Paik Hospital, College of Medicine, Inje University, Busan 47392, Korea.
Chang-Seon SongCollege of Veterinary Medicine, Konkuk University, Seoul 05029, Korea.ORCID https://orcid.org/0000-0002-4158-6402
Su Cheong YeomGraduate School of International Agricultural Technology, Seoul National University, Pyeongchang 25354, Korea.ORCID https://orcid.org/0000-0002-9491-5740
Soohyun KimLaboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea.ORCID https://orcid.org/0000-0002-0322-7935
Konkuk University · KRDaegu Catholic University · KRInje University · KRKorea Food Research Institute · KRMinistry of Food and Drug Safety · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.

Indexed as

Angiotensin-converting enzyme 2COVID-19Molecular targeted therapySARS-CoV-2Spike glycoprotein

Identifiers

PMID33728101
PMCPMC7937506
OpenAlexW3134431578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.